-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
728 million won the control of Dongbao Biotechnology
728 million won the control of Dongbao BiotechnologyRecently, Guoen shares announced that the company invested 360 million yuan in the transfer of 60 million shareholders Bao Biology stocks.
After the completion of the transaction, the proportion of shares held by Dongbao Biology rose to 21.
14% and became its controlling shareholder
.
By acquiring control of Dongbao Biotechnology, Guoen will further increase its deployment in the biomedicine and health care products business area, and use the listed company platform to effectively integrate resources, and give play to the synergistic effect of Yiqing Biotechnology and Dongbao Biotechnology in business areas such as biomedicine.
The announcement showed that on May 25th before the equity transfer, Guoen shares announced that it would subscribe for 65.
711 million A shares issued by Dongbao Bio to specific objects with its own funds of 368 million yuan at a price of 5.
6 yuan per share.
, Thus holding 11.
05% of Dongbao Biotech’s shares
.
After the share transfer, the shareholding ratio of Guoen shares will rise to 21.
It is understood that Toho Bio’s main products are gelatin and collagen, which are widely used in medicine, food and health products and other industries
.
Financial data shows that in the first quarter, the company achieved total operating income of 138 million yuan, an increase of 53.
It is noteworthy that, Toho biological main products of gelatin as the main raw material of medicinal hollow capsules, and the National Tsing Yi En stock subsidiary of biological medicinal hollow capsules have significant business synergies
.
Public information shows that Yiqing Bio is a professional manufacturer of basic pharmaceutical auxiliary materials.
Its main products include gelatin hollow capsules, enteric-coated gelatin hollow capsules, hypromellose (HPMC) hollow capsules, and pullulan hollow capsules.
The series has the production technology and production capacity of fish gelatin hollow capsules.
The products have passed the NSF certification of the United States and the BRC certification of the United Kingdom
.
At present, Yiqing Biotech can produce 20 billion high-quality hollow capsules annually, and has the supporting conditions for an annual output of 50 billion capsules
.
The company also plans to carry out more than 20 engineering and technological transformation projects to continuously improve the automation and intelligence of the production process.
Industry insiders pointed out that with the continuous growth of the pharmaceutical market's demand for medicinal capsules and the rapid development of the health care product market, the market for hollow capsules is very promising
.
In this context, Guoen shares control of Dongbao Bio will help to consolidate the leading position of its subsidiary Yiqing Bio in the hollow capsule market, and exert synergistic effects to fully grasp the opportunities for the development of the hollow capsule market
Guoen shares stated that the company will make full use of Dongbao Bio's high-quality industrial resources, play a synergistic effect with the company's business, enhance the company's competitive advantage in the gelatin industry chain business, and enhance the company's core competitiveness, anti-risk ability and sustainable development Ability
